Lumendi Reports First Incisionless Appendectomy Using Double-Balloon Endolumenal Interventional Platform
WESTPORT, CONNECTICUT --
Connecticut-based medical device innovator Lumendi, LLC reports the first endoscopic appendectomy using its DiLumenTM Endolumenal Interventional Platform (EIP). A patient underwent the purely endoscopic endolumenal appendectomy to remove a lesion previously identified at the appendiceal orifice. The patient reported no post-procedure pain, was discharged home from the endoscopy unit, resumed regular physical exercises and returned to work the morning after the appendectomy. Sergey V. Kantsevoy, MD, PhD, FJGES, Director of the Therapeutic Endoscopy at Melissa L. Posner Institute for Digestive Health and Liver Disease at Mercy Medical Center, Baltimore, Maryland, performed the procedure.
Appendectomies are traditionally performed through open or laparoscopic surgery, requiring an incision (or several punctures) of the abdominal wall. This can result in incisional pain, an increased risk of postoperative incisional hernias, and delays returning to work or resuming physical activity. Unlike previously reported Natural Orifice Transluminal Endoscopic Procedures (NOTES) transvaginal or transgastric appendectomy, access to the appendix was carried out via the patient’s cecum (first part of the colon), rather than through a gastric or vaginal wall incision.
To facilitate this less invasive endoscopic approach, Dr. Kantsevoy used a double balloon endolumenal interventional platform (DBEIP) consisting of a flexible overtube with two manually inflatable balloons: one behind the endoscope tip, the other with the ability to be advanced beyond the scope tip. On the significance of this DBEIP case, Dr. Kantsevoy said that “the stability and dynamic traction provided by DBEIP makes purely endoscopic endolumenal appendectomy technically feasible. It also eliminates the need for incisions or punctures of the abdominal wall, lessening the risk of post-surgical incisional hernias and intraperitoneal adhesions.”
According to Dr. Kantsevoy, “Endoscopic endolumenal appendectomy is less invasive than traditional surgical, laparoscopic, transvaginal or transgastric appendectomy. This novel endoscopic procedure will reduce post-procedure pain, will eliminate the need for hospital admission, and will assure an earlier return to work and regular physical activities, as compared with surgical, laparoscopic, transvaginal and transgastric appendectomy.”
“This new intervention demonstrates the options provided by the DiLumen platform,” said Dr. Peter Johann, Chairman & CEO of Lumendi. “Our focus is now on expanding the scope of DiLumen and DiLumen C2 beyond complex polyps, pre-cancerous lesions and non-invasive early cancers of the lower GI tract.”
Lumendi’s DiLumen EIP is an endolumenal device with a double-balloon design that aims to safely improve the navigation of the endoscope through the bowel, creating a stabilizing therapeutic zone inside the colon during endolumenal interventions, and minimizing potential mucosal injury. The device is compatible with most standard colonoscopes, aides the advancement of colonoscopes and endoscopic suturing devices through the colon, improves scope stability and provides dynamic multidirectional retraction during endolumenal colonic interventions. Clinicians have used DiLumen in more than 1,300 procedures across the U.S. and Europe.
DiLumen - Model C² - FDA Cleared Endoscopic Platform for Endolumenal Procedures
DiLumen - Model EZ Glide - Endolumenal Interventional Platform (EIP) with Hydrophilic EZ Glide Coating
DiLumen + - Model DR - Dynamic Retraction System
Related news
-
Recruitment of the smallest infants in the Connection study paused
IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol and clinical observations, enrolment of infants to Strata A has been paused awaiting a safety review by the Data Monitoring Committee (DMC). Subjects already randomized will continue treatment as per protocol, and enrolment of subjects into Strata B (750g-1000g) will continue. IBT is awaiting advice from the DMC before...
-
Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers based on novel microbial genetic insights, presented data from the largest analysis of microbiome function in Autism Spectrum Disorder (ASD), as well as preclinical activity of microbially-derived metabolites predicted to be reduced in ASD, during an oral poster presentation entitled, Predicted Metabolites from Multiple Microbiome Sequencing Datasets Modulate Autism...
-
Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced they are entering a strategic collaboration with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod. Under the terms of the agreement, Second Genome will utilize its proprietary sg-4sight...
-
Atmo Biosciences’ ingestible gas-sensing capsule to be used in Swedish IBS trial led by Professor Magnus Simrén
Atmo Biosciences’ world-first ingestible gas-sensing capsule is being used in a clinical trial led by renowned gastroenterologist Professor Magnus Simrén currently underway at Sweden’s University of Gothenburg. The trial named “The effects of carbohydrates in irritable bowel syndrome” is using the Atmo Gas Capsule digital biomarker platform to profile gases within the gut to help understand the mechanisms and benefits of carbohydrates in people with Irritable Bowel Syndrome (IBS),...
-
Lilly`s Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study
Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis (UC). LUCENT-2, a multicenter, randomized, double-blind, placebo-controlled maintenance study of mirikizumab in patients who have completed the 12-week LUCENT-1 induction study is ongoing. UC is a chronic inflammatory disease of the...
Customer comments
No comments were found for Lumendi Reports First Incisionless Appendectomy Using Double-Balloon Endolumenal Interventional Platform. Be the first to comment!